Teva Pharmaceutical Industries Ltd (TEVA)

32.80
0.19 0.58
NYSE : Health Care
Prev Close 32.61
Open 32.71
Day Low/High 32.70 / 33.25
52 Wk Low/High 31.90 / 58.16
Volume 3.60M
Avg Volume 10.85M
Exchange NYSE
Shares Outstanding 1.01B
Market Cap 33.02B
EPS 0.10
P/E Ratio 6.33
Div & Yield 1.36 (4.20%)

Latest News

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

A firestorm in Washington has created a fire sale for shares of this undervalued stock.

Sorry, the Correction Isn't Over

Why aren't people more concerned?

Teva To Present At The Cowen & Company 37th Annual Healthcare Conference

Teva To Present At The Cowen & Company 37th Annual Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 37 th Annual Healthcare Conference in Boston, MA.

Mylan's Governance May Be the Root of Its Problems

Mylan's Governance May Be the Root of Its Problems

The scandals plaguing the pharmaceutical company can be traced to lack of change at the board level.

Twenty More States Accuse Mylan, Teva and Others of Price Collusion

Twenty More States Accuse Mylan, Teva and Others of Price Collusion

Forty states have now sued the companies.

Teva Announces Launch Of Generic Pristiq® In The United States

Teva Announces Launch Of Generic Pristiq® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Pristiq ®1 (desvenlafaxine) extended-release tablets, 25, 50 and 100 mg, in the U.

Teva Announces Priority Review Granted By FDA For SD-809 For Treatment Of Tardive Dyskinesia

Teva Announces Priority Review Granted By FDA For SD-809 For Treatment Of Tardive Dyskinesia

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced the U.

Go With Allergan, Celgene and 'Big Mo'

Go With Allergan, Celgene and 'Big Mo'

These two large-cap drug giants should be core parts of any well-diversified portfolio.

Teva Files 2016 Annual Report On Form 20-F

Teva Files 2016 Annual Report On Form 20-F

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd.

5 Ways Allergan Can Keep Up Momentum

5 Ways Allergan Can Keep Up Momentum

Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.

Closing Bell: Apple Rallies to New Highs; U.S. Stocks End at Fresh Records for Day Three

Closing Bell: Apple Rallies to New Highs; U.S. Stocks End at Fresh Records for Day Three

Wall Street rallies to new records as leftover goodwill from Friday's rally pushes stocks to new heights.

Dow, S&P 500 and Nasdaq Score New Records for Third Straight Day

Dow, S&P 500 and Nasdaq Score New Records for Third Straight Day

The good vibes that carried Wall Street to new records last week lingered on into Monday's session.

Stocks Extend Gains, on Track to Close at Records for Third Day in Row

Stocks Extend Gains, on Track to Close at Records for Third Day in Row

The Dow Jones Industrial Average led Wall Street's gains on Monday on leftover goodwill from last week's Trump-inspired rally.

How to Trade Monday's Most Active Stocks: BofA, Vale, Zeltiq, Teva and More

How to Trade Monday's Most Active Stocks: BofA, Vale, Zeltiq, Teva and More

Here's how to trade seven of the most active names on the market.

Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq

Allergan Shares Rise on $2.5B Deal for Body-Sculptor Zeltiq

Allergan is buying body-sculptor Zeltiq. CEO Brent Saunders deems it to be the Botox of 10 years ago and he expects the deal to be immediately accretive.

Stocks Trade Above Record Closes, Apple Nears All-Time High

Stocks Trade Above Record Closes, Apple Nears All-Time High

Stocks edge higher on Monday as good vibes from Friday's record-breaking rally are sustained through the weekend.

Teva Claws Its Way Back With Earnings, Revenue Beat

Teva Claws Its Way Back With Earnings, Revenue Beat

The company had been free falling after CEO Erez Vigodman stepped down last week.

Market Recon: The Foundation Is Laid to Support This Rally

Market Recon: The Foundation Is Laid to Support This Rally

That support could become necessary should the blooming flower of tax reform come with a couple of thorns attached.

Teva Reports Full Year And Fourth Quarter 2016 Financial Results

Teva Reports Full Year And Fourth Quarter 2016 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the year and the quarter ended December 31, 2016.

Disney, Procter & Gamble and General Motors: Jim Cramer's Views

Disney, Procter & Gamble and General Motors: Jim Cramer's Views

Cramer shares his views about Disney, the most de-risked entertainment company ever, and wonders why, if Trump is so bad for stocks, there's no correction yet.

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Investors should keep an eye on interest rates and oil, but remember next week is still a week of big earnings reports, says Jim Cramer.

Teva Shares Decline After Company's CEO Exits

Teva Shares Decline After Company's CEO Exits

Teva's rich dividend yield may be too good to continue.

Dow Holds Gains, Nasdaq Scores New Record as Energy Shares Lag

Dow Holds Gains, Nasdaq Scores New Record as Energy Shares Lag

The Dow holds onto gains as oil prices fall and energy shares slide.

Cramer: If Trump Is So Bad for Stocks, Where's the Correction?

Cramer: If Trump Is So Bad for Stocks, Where's the Correction?

Yes, he's unpredictable, but is that a reason to sell?

Dow Remains Higher, S&P Slips as Oil Prices Drop, Energy Shares Lag

Dow Remains Higher, S&P Slips as Oil Prices Drop, Energy Shares Lag

Stocks lose steam Tuesday as oil prices fall and energy shares slide.

Despite Settling Decade-Long Suit, Mylan Shares Fall

Despite Settling Decade-Long Suit, Mylan Shares Fall

Mylan settled a pay-for-delay lawsuit over its narcolepsy drug, but its share prices are falling.

JIm Cramer: Investors Should Be Cautious With Teva Pharmaceutical

JIm Cramer: Investors Should Be Cautious With Teva Pharmaceutical

Jim Cramer discusses why investors should be cautious after Teva Pharmaceutical's CEO left the company.